Triple-Drug attack shows promise against untreatable liver cancer
NCT ID NCT07584018
First seen May 15, 2026 · Last updated Jun 19, 2026 · Updated 7 times
Summary
This study tests a three-drug combination (donafenib, chemotherapy via liver artery infusion, and sintilimab) as a first treatment for people with liver cancer that cannot be removed by surgery. About 90 adults aged 18-80 with advanced liver cancer will participate. The goal is to see if this approach can delay cancer progression and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.